Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 2Prostatic Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Leukemia, Plasma Cell 1Ganglioneuroblastoma 1Adenoma, Islet Cell 1

Interventions

dinutuximab 2Vincristine 2Topotecan 2Thiotepa 2Stem Cell Transplantation 2Radiation 2Platinum 2Melphalan 2Isotretinoin 2Etoposide 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2Carboplatin 21,2-diaminocyclohexaneplatinum II citrate 2sargramostim 1Transurethral Resection of Bladder 1Temozolomide 1Specimen Handling 1Razoxane 1Radiotherapy 1Proton Therapy 1Nuclear Medicine Department, Hospital 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Irinotecan 1Hematopoietic Stem Cell Transplantation 1Dexrazoxane 1Congresses as Topic 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × sargramostim × 30 days × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡